semaglutide 2.4 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Semasize Plus 2.4mg Injection (1

Signaling of prostaglandin E receptors, EP3 and EP4 facilitates wound healing and lymphangiogenesis with enhanced recruitment of M2 macrophages in mice

Cagrilintide also has one of the lowest GI odds ratios among the incretin and amylin compound class in a 2025 Bayesian network meta-analysis of multi-target obesity therapies the relevance for the stack is that adding cagrilintide to retatrutide may not compound GI burden as severely as adding a second GLP-1 agonist would

That might mean a small calorie reduction, more steps, better tracking accuracy, improved protein consistency, or a conversation with your provider

Wear protective eyewear to prevent eye injuries

Well-powered, controlled trials are needed to confirm efficacy and safety, identify optimal subgroups, and evaluate long-term outcomes